Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid
Romain Marignier(Hospices Civils de Lyon), Pascale Giraudon(Université Claude Bernard Lyon 1)
Cited by 55
Related Papers
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
|The Lancet|2019|722
Myelin-oligodendrocyte glycoprotein antibody-associated disease
|The Lancet Neurology|2021|518
Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide
|Frontiers in Neurology|2020|399
Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria
|The Lancet Neurology|2025|314
Worldwide Incidence and Prevalence of Neuromyelitis Optica
|Neurology|2020|303